fecal calprotectin
fecal calprotectin is an intervention with 13 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
8 of 10 finished
20.0%
2 ended early
2
trials recruiting
13
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients
Rutin Therapy Role in Reducing Ulcerative Colitis Severity
Fecal Calprotectin for Prediction of Esophageal Varices in Cirrhotic Patients
FC Change From Day 1 to Day 3 Associated With SALD
Clinical Trials (13)
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients
Rutin Therapy Role in Reducing Ulcerative Colitis Severity
Fecal Calprotectin for Prediction of Esophageal Varices in Cirrhotic Patients
FC Change From Day 1 to Day 3 Associated With SALD
Remote Monitoring of IBD
FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis
Fecal Calprotectin Level in Patients With Nosocomial Diarrhea
The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies
Effect of Real-world Tight Control Management of Inflammatory Bowel Disease
Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity
A Study to Determine Whether Urinary PGE-M Levels Correlate With Ulcerative Colitis Disease
All 13 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 13